| Pavilion Medical Home Care & Staffing, Llc | |
| 4115 Annandale Road, Suite 202, Annandale, Virginia 22003 | |
| (703) 299-9898 | |
| Name | Pavilion Medical Home Care & Staffing, Llc |
|---|---|
| Location | 4115 Annandale Road, Suite 202, Annandale, Virginia |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 497636 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 20105, 20109, 20110, 20111, 20112, 20120, 20121, 20124, 20136, 20143, 20147, 20148, 20151, 20152, 20155, 20164, 20165, 20166, 20169, 20170, 20171, 20175, 20176, 20190, 20191, 22003, 22015, 22025, 22030, 22031, 22032, 22033, 22041, 22042, 22043, 22044, 22046, 22060, 22066, 22079, 22101, 22102, 22124, 22150, 22151, 22152, 22153, 22172, 22180, 22181, 22182, 22191, 22192, 22193, 22201, 22202, 22203, 22204, 22205, 22206, 22207, 22209, 22301, 22302, 22304, 22305, 22306, 22307, 22308, 22309, 22310, 22311, 22312, 22314, 22315, 22401, 22405, 22406, 22407, 22408, 22553, 22554, 22556, 22905, 23455 |
| NPI Number | 1376620120 |
| Organization Name | PAVILION MEDICAL HOME CARE & STAFFING, LLC |
| Address | 4115 Annandale Rd, Suite 202, Annandale, VA 22003 |
| Phone Number | 703-299-9898 |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
| Quality Rating: |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 90.2 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 92 | 98.6 |
| How often the home health team checked patients’ risk of falling | 97.6 | 99.6 |
| How often the home health team checked patients for depression | 98.5 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 80.6 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 97.3 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 75.1 | 96.4 |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 76.2 | 79.6 |
| How often patients got better at getting in and out of bed | 87.4 | 81.1 |
| How often patients got better at bathing | 84 | 82.3 |
| How often patients’ breathing improved | 82.2 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 70.8 | 75 |
| How often home health patients had to be admitted to the hospital | 20.9 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 12.4 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 93.6 | 94 |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
The patient survey data of Pavilion Medical Home Care & Staffing, Llc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 80 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 69 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 60 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 73 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 66 | 78 |
News Archive
Scientists now have clues to how a gene mutation discovered in families affected with congenital heart disease leads to underdevelopment of the walls that separate the heart into four chambers.
Cancer researchers from Rice University suggest that a new man-made drug that's already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
The rapid growth of cell-based immunotherapy research has led to an increase in demand for methods to isolate specific immune cell populations from heterogeneous samples with high viability, purity and recovery efficiency. Quad Technologies ("Quad"), is meeting this need with its MagCloudz™ Streptavidin Cell Separation Kits and has partnered with The University of Massachusetts Medical School to evaluate the performance of its novel cell separation solution for the enrichment and purification of CD3+ T-cells from human umbilical cord blood.
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the second quarter ended June 30, 2010.
› Verified 4 days ago
Professional Healthcare Resources, Inc Location: 7619 Little River Turnpike, Suite 600, Annandale, Virginia 22003 Ratings: Phone: (703) 752-8760 | |
Esprit Home Healthcare Llc Location: 4209 Evergreen Lane Suite 101, Annandale, Virginia 22003 Ratings: Phone: (703) 998-7400 | |
Virginia Healthcare Services Location: 7010 Little River Turnpike, Suite 400, Annandale, Virginia 22003 Ratings: Phone: (703) 333-5288 | |
Pavilion Medical Home Care & Staffing, Llc Location: 4115 Annandale Road, Suite 202, Annandale, Virginia 22003 Ratings: Phone: (703) 299-9898 | |
Revival Homecare Agency Location: 5101c Backlick Road, Annandale, Virginia 22003 Ratings: Phone: (703) 341-6670 | |
Virginia Healthcare Services Of Fredericksburg Location: 7010 Little River Turnpike - Suite 110, Annandale, Virginia 22003 Ratings: Phone: (540) 479-8333 |